HIVPA produce a series of patient information leaflets (PILs) aimed at delivering the key information to patients, many of which have been produced in collaboration with NAM.
HIVPA leaflets should always be read in conjunction with the official patient information leaflet.
All leaflets will be reviewed annually or when there are changes to the information.
HIVPA Chair and Committee would like to acknowledge and thank Rosy Weston, Mel Snelling and Stephanie Tyler for their hard work, valued support and input into the preparation of Patient Information Leaflets.
Note: HIV Pharmacy Association Patient Information Leaflets and their content are covered by the Terms and Conditions as stated on the website.
Information to add contact details to HIV Pharmacy Association PILs documentation is available here.
Leaflets to support the 2022 antiretroviral contract
- ART Prescribing Toolkit: Prescribing PIL
- ART Prescribing Toolkit: Generics PIL
- Information for people switching from Eviplera® to generic emtricitabine/tenofovir disoproxil with Edurant® (rilpivirine)
- Information for people switching from Evotaz® to generic atazanavir and cobicistat
- Information for people switching from Evotaz® to generic atazanavir and ritonavir
- Information for people switching from Rezolsta® to cobicistat (Tybost) and generic darunavir
- Information for people switching from Rezolsta® to generic darunavir and ritonavir
- Information for people switching from Symtuza® to Descovy with cobicistat (Tybost) and generic darunavir
- Information for people switching from Symtuza® to Descovy with generic darunavir and ritonavir
Single Tablet Regimens
NRTIs (Fixed Dose Combinations)
- Tenofovir Disoproxil Fumarate
- Emtricitabine and Tenofovir Disoproxil (FTC/TD)
CCR5 Receptor Antagonists
- HIV Post Exposure Prophylaxis (PEP) – Generic tenofovir/emtricitabine with once daily raltegravir
- HIV Post Exposure Prophylaxis (PEP) – Branded tenofovir/emtricitabine with twice daily raltegravir
- HIV Post Exposure Prophylaxis (PEP) – Generic tenofovir/emtricitabine with twice daily raltegravir
- Newborn – HIV Post Exposure Prophylaxis (PEP)
- Dolutegavir And Pregnancy
- Switching from Sustiva 600mg tablets to generic Efavirenz 600mg tablets
- Switching from Viramune 400mg prolonged release to the generic prolonged release tablets
- Switching from Kivexa to generic Abacavir/Lamivudine tablets (Kivexa switch)
- Switching from Atripla to Truvada and generic Efavirenz
- Switching from Darunavir and Ritonavir to Rezolsta
- Switching from Atazanavir and Ritonavir to Evotaz
- Switching from Tenofovir disoproxil fumarate (Viread)® to generic tenofovir disoproxil
- Switching from Truvada to generic Tenofovir/Emtricitabine tablets
- Switching from Atripla to generic Tenofovir/Emtricitabine/Efavirenz tablets
- Switching from Prezista to generic darunavir
- Switching from Norvir to generic ritonavir
- Switching from Reyatez to generic Atazanavir
- Switching from Kaletra to generic lopinavir and ritonavir
- Switching from Epivir to generic Lamivudine
- Switching from Combivir to generic lamivudine/zidovudine (150/300mg)
- Switching from Combivir to generic lamivudine/zidovudine (150/300mg) both with and without contact details